However, a recent randomized clinical trial, conducted by Caldera et al., proved that higher doses of influenza vaccine in IBD individuals who received treatment with anti-TNF agents in monotherapy involved a greater antibody titre compared to standard doses (Caldera et al., 2020). This evidence concerns the gene TNF and inflammatory bowel disease.